Skip to main content
GMAB
NASDAQ Life Sciences

EC Approves Genmab's TEPKINLY for Relapsed/Refractory Follicular Lymphoma, First Bispecific Option

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$28.195
Mkt Cap
$17.026B
52W Low
$20.225
52W High
$35.43
52W Position info
39% above low
Off High info
20% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

GMAB sits 39% above its 52-week low of $20.225.

Summary

The European Commission has approved Genmab's TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. This marks the first and only bispecific-based therapy approved in Europe for this indication, offering a chemotherapy-free option. The approval is based on strong Phase 3 data, showing a 79% reduction in disease progression or death and a 74% complete response rate. This significantly expands the market opportunity for TEPKINLY and reinforces its potential as a core therapy across B-cell malignancies, building on recent positive trial results for the drug in other lymphoma types.

At the time of this announcement, GMAB was trading at $28.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17B. The 52-week trading range was $20.23 to $35.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GMAB - Latest Insights

GMAB
Oct 28, 2026, 9:41 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.12
Real-time Price: $55.45 info
Change: +$10.33 (+23%) info
Market Cap: $34.814B info
GMAB
Oct 26, 2026, 11:08 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $44.35
Real-time Price: $55.45 info
Change: +$11.09 (+25%) info
Market Cap: $34.814B info
GMAB
Oct 26, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $45.35
Real-time Price: $55.45 info
Change: +$10.09 (+22%) info
Market Cap: $34.814B info
GMAB
Oct 23, 2026, 11:56 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $40.64
Real-time Price: $55.45 info
Change: +$14.81 (+36%) info
Market Cap: $34.814B info
GMAB
Oct 13, 2026, 6:22 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $37.66
Real-time Price: $55.45 info
Change: +$17.79 (+47%) info
Market Cap: $34.814B info